



Optimise your counselling and treatment outcomes by recommending Saxenda® to your patients with obesity

## Saxenda® in summary



Patients achieved significant and sustained weight loss throughout 1-year and 3-year trials<sup>1-2</sup>



Patients also experienced significant improvements in cardiometabolic risk factors and complications<sup>1</sup>




Similar to natural GLP-1, Saxenda® works to decrease appetite and thereby reduce food intake<sup>1</sup>



The long-term safety profile of Saxenda® has been well established<sup>1,2</sup>

## How you can help



▶ how Saxenda® can help them lose weight, keep it off, and improve overall health



▶ them to speak to their physician about whether Saxenda® can be right for them



▶ them make the most of their physician appointment by preparing to discuss their health concerns and treatment options  
▶ if some of your patients are taking Saxenda®, help them with their weight management journey



Since its introduction, over **1 million patients** with obesity have been treated with Saxenda®<sup>3</sup>

### The 4-week dose escalation schedule<sup>1</sup>

Patients should follow a progressive dose escalation to achieve the maintenance dose of 3.0 mg/day



Encourage your patients on Saxenda® to enrol for access to the coach calls



#### References:

1. Saxenda® [summary of product characteristics]. 2. le Roux CW, Astrup A, Fujjoka K, et al; for the SCALE Obesity and Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399-1409 3. Adapted from IQVIA global sales data December 2018.

KS20SX00022

